非布司他联合血液透析治疗慢性肾脏病的疗效及对患者炎症因子水平、肾功能的影响

doi:10.3969/j.issn.1671-7171.2024.01.019

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1244 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To observe the clinical efficacy of nifedipine combined with hemodialysis in the treatment of chronic kidney disease (CKD),and effects on inflammation levels and renal function. 【Methods】 A total of 98 CKD patients who received regular hemodialysis(HD) in our hospital were randomly divided into the dialysis group (HD treatment) and the combined group (nifedipine combined with HD treatment), with 49 cases in each group. The levels of inflammatory factors, renal function, blood fat and oxidative stress indicators before and after treatment were compared between the two groups. The clinical efficacy and safety of the two groups were compared as well. 【Results】 After treatment, the levels of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α), adiponectin, uric acid, serum creatinine (Scr), urea nitrogen (BUN), 24 h urine protein quantification, β₂-microglobulin (β₂-MG), total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), malondialdehyde (MDA) in the combined group were lower than those in the dialysis group (P<0.05), while the glomerular filtration rate (eGFR), high-density lipoprotein cholesterol (HDL-C), catalase (CAT), glutathione peroxidase (GSH-Px) were higher than those in the dialysis group (P<0.05). The total effective rate of the combined group was higher than that of the dialysis group (P<0.05). There were no significant abnormality in blood routine and liver function before and after treatment in both groups, and no allergic reaction, drug intolerance or serious adverse reaction were found. 【Conclusion】 Nifedipine combined with HD can improve renal function and clinical efficacy of CKD patients, reduce inflammatory response and oxidative stress, reduce blood fat, and has high safety.

Key words： Kidney Diseases Chronic Disease Renal Dialysis Gout Suppressants/TU Treatment Outcome

Received: 31 August 2023

PACS:

R692

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DU Wenwen

Cite this article:

DU Wenwen. Effect of Nifedipine Combined with Hemodialysis on Inflammation Level and Renal Function in Patients with Chronic Kidney Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 70-73.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.01.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I1/70

[1] LI X, LINDHOLM B. Cardiovascular risk prediction in chronic kidney disease[J].Am J Nephrol,2022, 53(10):730-739.
[2] BROWN E A, ZHAO J, MCCULLOUGH K, et al. Burden of kidney disease, health-related quality of life, and employment among patients receiving peritoneal dialysis and in-center hemodialysis: findings from the DOPPS program[J].Am J Kidney Dis,2021, 78(4):489-500.
[3] NISHIZAWA H, MAEDA N, SHIMOMURA I. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease[J].Hypertens Res,2022, 45(4):635-640.
[4] GAO L G, WANG B, PAN Y, et al. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis[J].Clin Cardiol,2021, 44(7):907-916.
[5] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查,诊断及防治指南(2022年版)[J].中华肾脏病杂志, 2022, 38(5):453-464.
[6] JOHNSON R J, SANCHEZ LOZADA L G, LANASPA M A, et al. Uric acid and chronic kidney disease: still more to do[J].Kidney Int Rep,2022, 8(2):229-239.
[7] HASSAN W, SHRESTHA P, SUMIDA K, et al. Association of uric acid-lowering therapy with incident chronic kidney disease[J].JAMA Netw Open,2022, 5(6):e2215878.
[8] COHEN C, LE GOFF O, SOYSOUVANH F, et al. Glomerular endothelial cell senescence drives age-related kidney disease through PAI-1[J].EMBO Mol Med,2021, 13(11):e14146.
[9] COIMBRA S, ROCHA S, VALENTE MJ, et al. New insights into adiponectin and leptin roles in chronic kidney disease[J].Biomedicines,2022, 10(10):2642.
[10] FENG J N, YU L, LI H, et al. High serum β₂-microglobulin is a significant predictor of mortality in maintenance hemodialysis patients[J].Semin Dial,2023, 36(3):247-254.
[11] EBERT T, NEYTCHEV O, WITASP A, et al. Inflammation and oxidative stress in chronic kidney disease and dialysis patients[J].Antioxid Redox Signal,2021, 35(17):1426-1448.
[12] MIURA T, SAKUYAMA A, XU L, et al. Febuxostat ameliorates high salt intake-induced hypertension and renal damage in Dahl salt-sensitive rats[J].J Hypertens,2022, 40(2):327-337.
[13] YANG H T, LI R, LI Q, et al. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China[J].Int Urol Nephrol,2023, 55(5):1343-1352.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 296-298.